To include your compound in the COVID-19 Resource Center, submit it here.

Venclexta plus Rituxan combo meets in Phase III for CLL

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and AbbVie Inc. (NYSE:ABBV) reported data from the Phase III MURANO trial in 389 patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who had received one to three prior therapies

Read the full 397 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE